RESEARCH USE ONLY: All products are for laboratory research purposes only. Not for human or animal consumption.
By using this site, you confirm you are 21+ and acknowledge these products are not FDA approved.
AP
Ashley P.
✓ Verified Buyer
16 days ago
Everything looked good and matched the listing. Smooth checkout process.
CB
Chris B.
✓ Verified Buyer
27 days ago
Cold chain packaging was done right. Vial arrived intact and properly sealed.
Mechanism of Action
Semaglutide is a long-acting GLP-1 receptor agonist with 94% homology to native GLP-1. A C-18 fatty diacid enables albumin binding and ~7-day half-life. It enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and activates hypothalamic appetite-suppression circuits.
-
1
STEP 1: 14.9% mean weight loss at 68 weeks vs 2.4% with placebo in 1,961 adults
-
2
SELECT: 20% reduction in MACE in overweight/obese patients without diabetes
-
3
SUSTAIN-6: 26% reduction in cardiovascular events in T2DM patients
-
4
FLOW: 24% kidney disease progression risk reduction in T2DM-CKD patients
Once-weekly semaglutide in adults with overweight or obesity
PMID: 33567185
Wilding JPH, Batterham RL, et al.
— New England Journal of Medicine (2021)
Semaglutide 2.4mg produced 14.9% body weight reduction vs 2.4% placebo at 68 weeks (STEP 1)
Semaglutide and cardiovascular outcomes in obesity without diabetes
PMID: 37952131
Lincoff AM, Brown-Frandsen K, et al.
— New England Journal of Medicine (2023)
20% reduction in MACE with semaglutide in overweight/obese adults (SELECT trial)
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
PMID: 27633186
Marso SP, Bain SC, et al.
— New England Journal of Medicine (2016)
26% reduction in cardiovascular events with semaglutide vs placebo (SUSTAIN-6)
Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes
PMID: 38785209
Perkovic V, Tuttle KR, et al.
— New England Journal of Medicine (2024)
24% kidney disease progression risk reduction (FLOW trial)
Storage
Store lyophilized peptide at -20°C for long-term stability. Reconstituted solution should be stored at 2-8°C and used within 30 days. Avoid repeated freeze-thaw cycles.
Reconstitution
Reconstitute with bacteriostatic water (0.9% benzyl alcohol). Add solvent slowly down the side of the vial. Do not shake; gently swirl until dissolved.
Purity & Testing
Purity verified at ≥99.4% by HPLC. Each lot includes Certificate of Analysis with mass spectrometry confirmation and endotoxin testing.
Research Use Only
This product is intended for laboratory research purposes only. Not for human or animal consumption. Not FDA-approved for therapeutic use. Handle according to institutional biosafety protocols.
Frequently Asked Questions about Semaglutide 5mg
What is Semaglutide 5mg?
Semaglutide 5mg (GLP-1 Receptor Agonist) is a research-grade peptide supplied at 5mg/vial with ≥99.40% HPLC-verified purity. GLP-1 receptor agonist for metabolic research.
What purity is your Semaglutide 5mg?
Our Semaglutide 5mg is verified at ≥99.40% purity by High-Performance Liquid Chromatography (HPLC). Each lot includes a Certificate of Analysis with mass spectrometry confirmation and endotoxin testing results.
How should I store Semaglutide 5mg?
Store lyophilized Semaglutide 5mg at -20°C for optimal long-term stability. After reconstitution with bacteriostatic water, store at 2-8°C and use within 30 days. Avoid repeated freeze-thaw cycles to maintain peptide integrity.
Do you offer bulk discounts on Semaglutide 5mg?
Yes. We offer tiered pricing: 3-vial packs include a 7% discount and 5-vial packs include a 14% discount. All multi-vial options are available on this product page above.
Is Semaglutide 5mg third-party tested?
Yes. Every batch of Semaglutide 5mg is independently tested by third-party laboratories using HPLC and mass spectrometry. Certificate of Analysis available upon request. All products are manufactured under ISO-compliant conditions.
Related Metabolic Regulation & Energy Homeostasis Peptides